Sverige - svenska - Läkemedelsverket (Medical Products Agency)

dopharma research b.v. - bromhexinhydroklorid - pulver för användning i dricksvatten/mjölk - 20 mg/g - laktosmonohydrat hjälpämne; propylenglykol hjälpämne; bromhexinhydroklorid 20 mg aktiv substans - anka, fjäderfä, nöt, svin

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

dopharma research b.v. - toltrazuril - oral suspension - 50 mg/ml - toltrazuril 50 mg aktiv substans; natriumbensoat hjälpämne; propylenglykol hjälpämne - svin

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

dopharma research b.v. - flubendazol - suspension för användning i dricksvatten - 200 mg/ml - natriumbensoat hjälpämne; propylparahydroxibensoat hjälpämne; propylenglykol hjälpämne; polysorbat 80 hjälpämne; metylparahydroxibensoat hjälpämne; flubendazol 200 mg aktiv substans; cetostearylalkohol hjälpämne - fjäderfä, svin

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

dopharma research b.v. - tylosin - injektionsvätska, lösning - 200000 ie/ml - bensylalkohol hjälpämne; tylosin 200000 ie aktiv substans; propylenglykol hjälpämne - får, get, nöt, svin

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

chanelle pharmaceuticals manufacturing ltd - fipronil - spot-on, lösning - 134 mg - fipronil 134 mg aktiv substans; butylhydroxitoluen hjälpämne; butylhydroxianisol hjälpämne; bensylalkohol hjälpämne - fipronil - hund

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

chanelle pharmaceuticals manufacturing ltd - fipronil - spot-on, lösning - 268 mg - bensylalkohol hjälpämne; butylhydroxitoluen hjälpämne; fipronil 268 mg aktiv substans; butylhydroxianisol hjälpämne - fipronil - hund

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

chanelle pharmaceuticals manufacturing ltd - fipronil - spot-on, lösning - 402 mg - fipronil 402 mg aktiv substans; bensylalkohol hjälpämne; butylhydroxitoluen hjälpämne; butylhydroxianisol hjälpämne - fipronil - hund

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

chanelle pharmaceuticals manufacturing ltd - fipronil - spot-on, lösning - 50 mg - butylhydroxianisol hjälpämne; butylhydroxitoluen hjälpämne; bensylalkohol hjälpämne; fipronil 50 mg aktiv substans - fipronil - katt

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

chanelle pharmaceuticals manufacturing ltd - fipronil - spot-on, lösning - 67 mg - butylhydroxianisol hjälpämne; butylhydroxitoluen hjälpämne; bensylalkohol hjälpämne; fipronil 67 mg aktiv substans - fipronil - hund

Europeiska unionen - svenska - EMA (European Medicines Agency)

mabxience research sl - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastiska medel - alymsys in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. alymsys in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. alymsys in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with alymsys in combination with capecitabine. alymsys, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer other than predominantly squamous cell histology. alymsys, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non squamous non small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations. alymsys in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. alymsys, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer. alymsys, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. alymsys, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. alymsys, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix.